Sign in

Carl Burns

Research Analyst at Analyst

Carl Burns is an equity analyst who specializes in investment research, with a particular focus on providing actionable insights for institutional and retail investors. His professional coverage areas and specific companies, quantitative performance metrics, and industry recognition could not be verified from public search results. Carl has held analyst roles in the financial sector, but details about his career timeline, previous employers, and securities licensing are also not currently available. As of now, there is no confirmation of his FINRA registration, notable achievements, or credentials due to limited publicly accessible information.

Carl Burns's questions to Nutex Health (NUTX) leadership

Question · Q3 2025

Carl Burns asked about the revised timeline for new hospital startups to reach break-even, considering the history and success of the IDR process, and inquired about opportunities to acquire existing hospitals similar to the Homer G. Phillips project.

Answer

CFO Jon Bates stated that while IDR success improves profitability, the break-even timeline for startups is still budgeted at 12-15 months, potentially shifting by a quarter, due to the 5-7 month payment cycle for IDR claims. CEO Tom Vo confirmed the Homer G. Phillips Hospital in St. Louis is set to open by year-end, and Nutex Health is actively seeking to acquire existing hospitals that meet their strategic criteria, though such opportunities are rare.

Ask follow-up questions

Fintool

Fintool can predict Nutex Health logo NUTX's earnings beat/miss a week before the call

Question · Q3 2025

Carl Burns asked about the revised timeline for new hospital startups to reach break-even, considering the IDR process, and if Nutex Health is pursuing other acquisition opportunities similar to the Homer G. Phillips Hospital in St. Louis.

Answer

CFO Jon Bates explained that while IDR claims take 5-7 months for full payment, the break-even timeline for startups might improve by a quarter from the usual 12-15 months, with a more significant impact on earlier profitability in years one and two. CEO Tom Vo confirmed the St. Louis hospital is set to open in mid-to-late December, targeting a healthcare desert. He also stated that Nutex Health actively seeks to acquire existing hospitals that meet their strategic criteria, though such opportunities are rare.

Ask follow-up questions

Fintool

Fintool can write a report on Nutex Health logo NUTX's next earnings in your company's style and formatting

Carl Burns's questions to TriSalus Life Sciences (TLSI) leadership

Question · Q4 2024

Carl Burns inquired about the specific clinical applications driving the uptake of the TriNav large vessel system and sought to quantify the impact of the new CMS reimbursement code for TARE mapping procedures.

Answer

CEO Mary Szela and Medical Director Dr. Richard Marshall explained that the TriNav large vessel system is primarily being used in TARE procedures for larger vessels and low-bar applications, particularly in patients with neuroendocrine tumors. Regarding the new CMS code for mapping, Szela clarified it applies to Medicare patients (about 25% of the market) who were previously not using TriNav for mapping due to reimbursement concerns, noting this was not baked into guidance and represents potential upside.

Ask follow-up questions

Fintool

Fintool can predict TriSalus Life Sciences logo TLSI's earnings beat/miss a week before the call